Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year
July 3rd 2024Repeated 0.1-ml intravireal injections of lampalizumab, antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D, seem to be associated with a low risk of elevated IOP
Read More